Navegando por Palavras-chave "rosuvastatin"

Agora exibindo 1 - 3 de 3
  • Nenhuma Miniatura disponível
    Item
    Somente Metadadados
    Achieving 2003 European lipid goals with rosuvastatin and comparator statins in 6743 patients in real-life clinical practice: DISCOVERY meta-analysis analysis
    (Librapharm, 2006-06-01) Middleton, A.; Binbrek, A. S.; Fonseca, F. A. H.; Wilpshaar, W.; Watkins, C.; Strandberg, T. E.; Fowey Surg; Rashid Hosp; Universidade Federal de São Paulo (UNIFESP); AstraZeneca; Univ Helsinki
    Background: There is an increasing body of evidence to support the benefits of reducing low-density lipoprotein cholesterol ( LDL- C) levels and this has been reflected in a lowering of LDL- C goals recommended by international guidelines. Therefore, there is a growing need for effective lipid-modifying therapies to optimise the achievement of these more stringent LDL- C goals.Objective: A meta-analysis of data pooled from five studies participating in the DISCOVERY ( DIrect Statin COmparison of LDL- C Values: an Evaluation of Rosuvastatin therapY) Programme was performed to compare the effect of rosuvastatin treatment with other statins in real-life clinical practice.Results: These studies included 6743 patients with hypercholesterolaemia from different ethnicities, countries and cultural environments. the meta-analysis showed that significantly more patients receiving rosuvastatin 10 mg achieved the 2003 European LDL- C goals compared with those who received atorvastatin 10 mg or simvastatin 20 mg ( p < 0.001 for both comparisons). A significantly greater proportion of patients receiving rosuvastatin 10 mg also achieved the 2003 European total cholesterol goal compared with those on atorvastatin 10 mg ( p < 0.001).Conclusions: the meta-analysis showed that rosuvastatin was more effective than comparator statins at lowering LDL- C levels and enabling patients to achieve lipid goals at recommended start doses. in addition, all statins studied were well tolerated and confirmed that rosuvastatin had a similar safety profile to other statins.
  • Nenhuma Miniatura disponível
    Item
    Somente Metadadados
    The DISCOVERY PENTA study: a DIrect Statin COmparison of LDL-C value - an Evaluation of Rosuvastatin therapY compared with atorvastatin
    (Librapharm, 2005-08-01) Fonseca, Francisco Antonio Helfenstein [UNIFESP]; Ruiz, A.; Cardona-Munoz, E. G.; Silva, J. M.; Fuenmayor, N.; Marotti, M.; DISCOVERY PENTA investigators; Universidade Federal de São Paulo (UNIFESP); Pontificia Univ Javeriana; Univ Guadalajara; Univ Coimbra; Hosp Miguel Perez Carreno; AstraZeneca
    Background. International guidelines emphasize the need to achieve recommended low-density lipoprotein cholesterol (LDL-C) levels in order to reduce morbidity and mortality associated with coronary heart disease (CHD). However, many patients with hypercholesterolemia fail to achieve LDL-C goals on treatment.Objective: the primary objective was to compare the efficacy of rosuvastatin and atorvastatin for enabling patients to achieve National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) LDL-C goals. Secondary objectives were European LDL-C goal achievement, changes in the lipid profile, and safety. Research design and methods: This 12-week, multicenter, multinational, randomized, open-label trial compared the efficacy and safety of rosuvastatin 10 mg with atorvastatin 10 mg in statin-naive and switched patients with primary hypercholesterolemia from Brazil, Colombia, Mexico, Portugal, and Venezuela.Results: A total of 1124 patients with similar baseline characteristics were randomized to the two treatment groups. After 12 weeks of treatment, a significantly greater percentage of patients receiving rosuvastatin 10mg compared with atorvastatin 10 mg achieved NCEP ATP III LDL-C goals (71.2% vs 61.4%, p < 0.001), 1998 European LDL-C goals (73.5% vs 59.2%, p < 0.001) and 2003 European LDL-C goals (58.9% vs 44.6%, p < 0.001). Rosuvastatin treatment was associated with significant reductions in LDL-C and total cholesterol (TC) and, in statin-naive patients, a significant increase in high-density lipoprotein cholesterol (HDL-C) compared with atorvastatin treatment. Both treatments were well tolerated with a similar incidence of adverse events. Clinically significant elevations in creatinine, creatine kinase or hepatic transaminases were low and similar between treatment groups.Conclusions: Rosuvastatin 10 mg is significantly more effective at achieving NCEP ATP III and European LDL-C goals, lowering LDL-C and TC in both naive and switched patients and increasing HDL-C in naive patients than atorvastatin 10 mg, with a similar safety and tolerability profile. This study also provides evidence regarding the comparative effects of rosuvastatin versus atorvastatin in Latin American and Portuguese populations.
  • Nenhuma Miniatura disponível
    Item
    Somente Metadadados
    Effect of rosuvastatin and sevelamer on the progression of coronary artery calcification in chronic kidney disease: a pilot study
    (Dustri-verlag Dr Karl Feistle, 2013-07-01) Lemos, Marcelo M. [UNIFESP]; Watanabe, Renato [UNIFESP]; Carvalho, Aluizio B. [UNIFESP]; Jancikic, Alessandra D. B. [UNIFESP]; Sanches, Fabiana M. R. [UNIFESP]; Christofalo, Dejaldo M. [UNIFESP]; Draibe, Sergio A. [UNIFESP]; Canziani, Maria Eugenia F. [UNIFESP]; Universidade Federal de São Paulo (UNIFESP)
    Introduction: Coronary artery calcification (CAC) is highly prevalent among chronic kidney disease (CKD) patients and its strong association with mortality has been recognized early in the course of CKD. the aim of the present study was to test the effect of rosuvastatin and sevelamer hydrochloride on the progression of CAC in nondialyzed CKD patients. Methods: An open-label, randomized and controlled pilot study was conducted including 117 CKD patients (62% men, 56.9 +/- 11.2 years, eGFR 36 +/- 16.5 ml/min) Patients were randomly assigned to rosuvastatin (n = 38; 10 mg/day), to sevelamer hydrochloride (n = 38; 2,400 mg/day) and to control (n = 41) groups. CAC (by multislice computed tomography) and biochemical analyses were performed at baseline and after 24 months. Results: At baseline, CAC was observed in 55%, 58% and 61% of patients in the rosuvastatin, sevelamer hydrochloride and control groups, respectively (p = 0.87). Calcium score at baseline as well as its absolute and relative changes during 24 months were similar among the groups. Low density lipoprotein cholesterol (LDL-c) was higher and decreased significantly in the rosuvastatin group (p < 0.01). the analysis adjusting for LDL-c showed that the drug regimens were not associated with the progression of CAC (drug effect p = 0.85; time-effect p < 0.001; interaction p = 0.76). Conclusions: Treatment with rosuvastatin and sevelamer hydrochloride may not delay the progression of CAC in non-dialysis dependent CKD patients.